`
The global diabetes devices market size 2026 was valued at USD 35.71 billion in 2025 and is projected to reach USD 38.77 billion by 2026, growing at a CAGR of 8.55% during the forecast period. North America led the global market, accounting for 40.54% of the revenue share in 2025
The market's sustained demand stems from the chronic nature of diabetes, the need for continuous disease management, and rising prevalence worldwide. Rapid urbanization, sedentary lifestyles, and increasing obesity rates are among the key contributors fueling this growth.
Key Market Drivers
- Technological Innovation The introduction of novel, technologically advanced products is a primary growth engine. Key milestones include:
- Abbott's FDA-approved FreeStyle Libre Flash Glucose Monitoring System (September 2017), using an arm-worn sensor for glucose tracking.
- Tandem Diabetes Care's FDA-cleared t:slim X2 insulin pump (February 2019), the first interoperable insulin pump for children and adults.
- A partnership between Bigfoot Biomedical and Eli Lilly (January 2019) to develop AI-driven insulin dosing optimization.
- Rising Global Diabetes Prevalence According to the International Diabetes Federation, approximately 425 million adults were living with diabetes in 2017, a figure projected to climb to 630 million by 2045. China, India, the U.S., Brazil, and Mexico collectively account for 55–60% of the global diabetic population. Obesity — a key risk factor — affects an estimated 650 million adults globally (WHO, 2016).
- Digitalization and Connected Care The market is undergoing a structural transformation driven by AI, automation, and data-centric care models. Continuous glucose monitoring (CGM) has become foundational, while automated insulin delivery systems — combining sensors, algorithms, and pumps — are redefining patient management through closed-loop approaches.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetes-devices-market-100803
Market Segmentation
By Device Type
- Monitoring Devices held the largest market share in 2018 and are expected to grow at a faster pace. This segment includes:
- Continuous Glucose Monitoring (CGM) Systems — the highest-growth subsegment, offering real-time data streams, predictive alerts, and digital platform integration.
- Self-Monitoring Blood Glucose (SMBG) Systems — widely adopted but facing margin pressure due to commoditization.
- Treatment Devices — including insulin pens, pumps, syringes, jet injectors, and closed-loop automated delivery platforms — benefit from high switching costs, long patient lifecycles, and strong reimbursement support.
By Distribution Channel
- Retail Sales hold the highest share and are projected to grow at a higher CAGR, driven by the penetration of private-label brands at competitive prices and increased self-management by patients.
- Institutional Sales (hospitals, clinics) dominate advanced device adoption, supported by reimbursement frameworks and clinician-driven procurement.
Regional Analysis
|
Region |
Status |
|
North America |
Largest share (40.54% in 2018); high CGM and automated insulin delivery adoption |
|
Europe |
Mature market with pricing controls; Central/Eastern Europe offers growth potential |
|
Asia-Pacific |
Fastest-growing region; driven by rising diabetes rates and urbanization |
|
Latin America & MEA |
Emerging markets; growth supported by improving healthcare infrastructure |
Competitive Landscape
The market is highly competitive, dominated by a small group of global players. F. Hoffmann-La Roche Ltd. and Medtronic held the highest revenue shares in 2018. Other key players include:
- Abbott
- BD (Becton, Dickinson and Company)
- Tandem Diabetes Care, Inc.
- Novo Nordisk A/S
- Sanofi
- B. Braun Melsungen AG
- Eli Lilly and Company
Competitive advantage is increasingly shaped by platform capability, data integration, and lifecycle value rather than device performance alone. Strategic activity includes partnerships with digital health platforms, acquisitions to expand software/analytics reach, and investment in next-generation sensing and closed-loop technologies.
Key Industry Developments
- May 2021 – Medtronic received European CE Mark approval for the InPen connected insulin pen and the Guardian 4 CGM sensor.
- March 2021 – Roche launched the Accu-Chek Instant system with Bluetooth connectivity to the mySugr app for personalized diabetes management.
- June 2020 – Abbott and Tandem Diabetes Care finalized an agreement to develop integrated CGM and insulin delivery solutions.
Market Outlook & Opportunities
Short-term growth is backed by rising diabetes prevalence and expanding reimbursement coverage. Mid-term acceleration is expected as CGM systems and automated insulin delivery gain wider clinical acceptance. Long-term momentum will be shaped by:
- AI-powered predictive analytics and personalized care
- Remote monitoring and telehealth integration
- Expansion into underserved markets in Asia-Pacific and Latin America
- White-space opportunities in metabolic health and chronic disease management platforms
Companies best positioned for future growth are those aligning hardware innovation with software services, addressing affordability and access, and delivering measurable clinical outcomes.
`
Top comments (0)